We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Reviews Stalevo Trial Data for Risk of Prostate Cancer
FDA Reviews Stalevo Trial Data for Risk of Prostate Cancer
April 14, 2010
Orion and Novartis’ Parkinson’s combination drug Stalevo is the focus of an ongoing FDA safety investigation to determine whether the treatment
is associated with an increased risk of prostate cancer.